Provided by Tiger Trade Technology Pte. Ltd.

Atea Pharmaceuticals, Inc.

5.51
+0.08001.47%
Volume:100.10K
Turnover:545.71K
Market Cap:441.93M
PE:-2.63
High:5.53
Open:5.39
Low:5.25
Close:5.43
52wk High:6.45
52wk Low:2.78
Shares:80.20M
Float Shares:60.05M
Volume Ratio:0.44
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0959
EPS(LYR):-1.9430
ROE:-58.14%
ROA:-36.72%
PB:2.16
PE(LYR):-2.84

Loading ...

Atea Pharmaceuticals price target raised to $7 from $6 at Morgan Stanley

TIPRANKS
·
Aug 17

Assembly Biosciences Q2 Net Loss Narrows as Revenue Rises

Reuters
·
Aug 14

Morgan Stanley Adjusts PT on Atea Pharmaceuticals to $7 From $6, Maintains Equalweight Rating

MT Newswires Live
·
Aug 13

Analysts’ Top Healthcare Picks: Cardinal Health (CAH), Atea Pharmaceuticals (AVIR)

TIPRANKS
·
Aug 13

Atea Pharmaceuticals Q2 Loss Narrows as HCV Trial Expenses Decline

Reuters
·
Aug 13

Atea Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Atea Pharmaceuticals Q2 EPS $(0.41) Beats $(0.56) Estimate

Benzinga Earnings
·
Aug 13

Press Release: Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 13

Atea Pharmaceuticals, Inc. Expected to Post a Loss of 56 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

GlobeNewswire
·
Aug 05

Atea Pharmaceuticals, Inc. Expected to Post a Loss of 56 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Atea Pharmaceuticals Shares Positive Results from Hepatitis C Trial

Dow Jones
·
Jul 28

Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints

TIPRANKS
·
Jul 28

Atea Says Phase 3 C-beyond Trial Shows Hepatitis C Combo Bemnifosbuvir/ruzasvir Matches Epclusa on Cure Rates

Reuters
·
Jul 28

Atea Pharmaceuticals - C-Forward Phase 3 Trial to Report Topline Results in Early 2027

THOMSON REUTERS
·
Jul 28

Atea Pharmaceuticals - in C-Beyond, Bem/Rzr Generally Safe with no Drug-Related Serious Adverse Events in Phase 3 Trial

THOMSON REUTERS
·
Jul 28

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-Beyond North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

THOMSON REUTERS
·
Jul 28

NASDAQ Trade Halt Halt News Pending at 06:55 Am

Reuters
·
Jul 28

Atea Advances Antiviral Pipeline With New Drug Interaction Study in Opioid Therapy

TIPRANKS
·
Jul 17

Atea Pharmaceuticals Announces Availability of Press Release on At-587 Phase 1 Trial Start

Reuters
·
Jul 14